Multiple Myeloma | Specialty

Considering Other CAR T-Cell Strategies in R/R Myeloma

June 26th 2019

Establishing the Potential of AMG 420 in R/R Multiple Myeloma

June 26th 2019

Considering Oral Selinexor for Relapsed/Refractory Myeloma

June 26th 2019

Venetoclax in Relapsed/Refractory Myeloma: The BELLINI Trial

June 26th 2019

Subcutaneous Daratumumab in R/R Myeloma: The COLUMBA Trial

June 26th 2019

Emerging Therapies for Relapsed/Refractory Multiple Myeloma

June 26th 2019

Newly Diagnosed Myeloma: Transplant Ineligibility and Treatment

June 26th 2019

Newly Diagnosed Transplant-Eligible Myeloma: The Role of MRD

June 26th 2019

Trial Data in Newly Diagnosed Transplant-Eligible Myeloma

June 26th 2019

Treating Myeloma: Newly Diagnosed Transplant-Eligible Patients

June 26th 2019

Clinical Trials' Impact on Smoldering Myeloma Management

June 26th 2019

Smoldering Myeloma: Treatment and Risk Stratification

June 26th 2019

FDA Lifts Partial Clinical Hold on Venetoclax Myeloma Trial

June 25th 2019

The FDA has lifted a partial clinical hold that was placed on the phase III CANOVA (M13-494; NCT03539744) trial, which is examining venetoclax in combination with pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma that harbors t(11;14), according to AbbVie, the company that co-develops the BCL-2 inhibitor with Roche.

Rapid Changes in Multiple Myeloma Provide a Windfall of Treatment Options

June 21st 2019

S. Vincent Rajkumar, MD, discusses the rapidly changing landscape for the treatment of multiple myeloma, the future of immunomodulatory drugs, and whether quadruplet regimens will become more frequent.

Dr. Rajkumar on Quadruplet Regimens in Multiple Myeloma Treatment

June 20th 2019

S. Vincent Rajkumar, a professor of Medicine at the Mayo Clinic, Rochester, Minnesota, discusses the prevalence of quadruplet regimens in treating patients with multiple myeloma.

Dr. Pecora on Updated MAIA Data in Multiple Myeloma

June 20th 2019

Andrew Pecora, MD, FACP, CPE, president physician enterprise, chief innovation officer, John Theurer Cancer Center, Hackensack Meridian Health, discusses the impact age has on the efficacy and safety of daratumumab in combination with lenalidomide and dexamethasone (DRd) in patients with transplant-ineligible newly diagnosed multiple myeloma (NDMM) as part of the MAIA study.

Phase III BELLINI Data Showcase Safety Concerns With Venetoclax in Multiple Myeloma

June 16th 2019

Despite promising progression-free survival and response data with venetoclax in combination with bortezomib and dexamethasone, an increased number of deaths due to infection in the experimental arm marred overall survival findings in patients with relapsed/refractory multiple myeloma.

Elotuzumab Triplet Continues to Show Survival Benefit in Relapsed/Refractory Myeloma

June 14th 2019

The triplet regimen of elotuzumab plus pomalidomide and dexamethasone led to a 46% reduction in the risk of death compared with pomalidomide/dexamethasone alone in patients with relapsed/refractory multiple myeloma, according to updated findings of the phase II ELOQUENT-3 trial.

Dr. Chari on the INSIGHT MM Study on Multiple Myeloma

June 14th 2019

Ajai Chari, MD, Icahn School of Medicine at Mount Sinai, discusses INSIGHT MM (NCT02761187), the largest global, prospective, non-interventional, observational study on multiple myeloma to date.

Innovation Fuels Survival Gains in Multiple Myeloma

June 12th 2019

While the expansion of therapeutic opportunity in multiple myeloma has been incremental in some ways, it’s been continuous and, when seen in aggregate, the impact is considerable.